Certbie
Log InSign Up
Question 1 of 30
Imagine vTv Therapeutics is conducting a pivotal Phase III trial for a promising new drug. Midway through, a key regulatory agency issues a revised data submission mandate that significantly alters the required format and types of ancillary data to be collected, creating an immediate need for protocol amendments and additional analytical resources. Which of the following strategic responses best exemplifies adaptability and proactive problem-solving in this context?
Immediately halt all data collection, convene a broad internal task force to comprehensively redesign the entire data collection and analysis framework from scratch, and then resume operations after full approval of the new framework.
Proceed with the original data collection plan while initiating a separate, parallel project to gather the newly mandated ancillary data, hoping to integrate it retrospectively without impacting the primary trial timeline.
Conduct a rapid assessment of the new regulatory requirements, consult with relevant internal experts and external regulatory consultants, develop a revised protocol amendment outlining specific changes to data collection and analysis, and communicate this revised plan transparently to all stakeholders, including clinical sites and regulatory bodies, for swift implementation.
Lobby the regulatory agency to delay or waive the new data submission requirements, citing the advanced stage of the ongoing trial and the potential disruption to public health initiatives.